Injection Drug use Practices and HIV infection among People Who Inject Drugs in Kigali, Rwanda.

Authors

Jean Olivier Twahirwa Rwema, MD, MPH ¹, Vianney Nizeyimana, MD, MPH ², Neia Prata Menezes, MPH ¹, Nneoma E. Okonkwo ³, Amelia Aibina Mazzei, ND, MPH ^{4,5}, Sulemani Muhirwa ², Athanase Rukundo, MD, MSc ², Lisa Lucas, MSc ¹, Audace Niyigena, MD ⁶, Jean Damascene Makuza, MD, MSc ^{7,8,9}, Chris Beyrer, MD, MPH ¹, Stefan D. Baral MD, MPH ¹, Afloodis Kagaba, MD, MSc ²

Affiliations

1. Department of Epidemiology, Key Populations Program, Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
2. Health Development Initiative, Kigali, Rwanda
3. School of Medicine, Johns Hopkins University, Baltimore, MD
4. Emory University School of Medicine, Atlanta GA
5. Projet San Francisco, Kigali Rwanda
6. Département de Psychiatrie, Service d'addictologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
7. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
8. BC Center for Disease Control, Vancouver, BC, Canada
9. Rwanda Biomedical Center, Kigali, Rwanda

Correspondence: Jean Olivier Twahirwa Rwema, MD, MPH, Department of Epidemiology, Key Populations Program, Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street E 7133 Baltimore, MD 21205 (email: jtwahir1@jhu.edu)

Email Addresses of Authors

Jean Olivier Twahirwa Rwema: jtwahir1@jhmi.edu
Vianney Nizeyimana: dvianney@hdirwanda.org
Neia Prata Menezes: npratam1@jhmi.edu
Nneoma E. Okonkwo: nneoma@jhmi.edu
Athanase Rukundo: athanase@hdirwanda.org
Amelia Aibina Mazzei: amazze2@emory.edu
Sulemani Muhirwa: muhisule@hdirwanda.org
Lisa Lucas: llucas11@jhmi.edu

Audace Niyigena: audace.niyigena@hcuge.ch

Jean Damascène Makuza: makorofr@gmail.com

Chris Beyrer : cbeyrer@jhu.edu

Stefan Baral: sbaral@jhu.edu

Aflodis Kagaba: kagaba@hdirwanda.org

Abstract

Background

In Rwanda, epidemiological data characterizing people who inject drugs (PWID) and their burden of HIV are limited. We examined injecting drug use (IDU) history, practices, and HIV infection in a sample of PWID in Kigali.

Methods

From October 2019–February 2020, 322 PWID aged ≥ 18 were enrolled in a cross-sectional study using convenience sampling in Kigali. Participants underwent a structured interview and HIV testing. We used Poisson regression with robust variance estimation to assess IDU practices associated with HIV infection.

Results

The median age was 28 years (IQR:24-31) and 81% (248) were male. The median age at first injection was 23 years (IQR:20-27). HIV prevalence was 9.5% (95% CI:8.7-9.3).

In the six months preceding the study, heroin was the primary drug of choice for 99% (303); but cocaine and methamphetamine were also reported by 10% (31) and 4% (12) respectively. Furthermore, 31% (94) and 33% (103) of participants, shared or reused needles in the previous six months, respectively. Up to 43% (133) knew someone who died from a drug-related overdose. PWID reporting sharing needles at least half the time in the previous six months had increased likelihood of HIV-infection, compared to those who did not (aPR: 2.67; 95% CI:1.23–5.78).

Conclusion

HIV infection was common in this sample of PWID in Kigali. The high prevalence of needle reuse and sharing practices highlight significant risk for onward transmission and acquisition of HIV and hepatitis B and C. PWID-focused harm reduction services, including needle and syringe programs, safer injection education, naloxone distribution, and substance use disorder treatment programs, are needed in Rwanda.

Key words: People who Inject Drugs, HIV, Injection Drug Use, Rwanda

Introduction

Sustained improvements in access to HIV prevention and treatment have been made over the last decade in Eastern and Southern Africa (ESA), the region with the greatest burden of HIV globally¹. As a result, since 2010, AIDS-related deaths in the region have fallen by 49% and new HIV infections by 38%¹. However, not all people affected or infected by HIV have been reached by these services equally. Key populations (KPs) including men who have sex with men (MSM), transgender women (TGW), female sex workers (FSW) and people who inject drugs (PWID) are not adequately reached with HIV services and remain at a high risk of HIV transmission and acquisition. For instance, HIV prevalence among PWID in ESA is estimated to be around 19%, almost double the prevalence among other adults in the region¹.

Globally, 15 million people report injection drug use (IDU), with increasing numbers in countries across sub-Saharan Africa (SSA)^{2,3}. Estimates of IDU range from 0% to 3% among the general adult populations in SSA. IDU is associated with an increased risk of acquiring HIV and other sexually transmitted infections (STIs), hepatitis B (HBV), hepatitis C (HCV), and other blood-borne infections, and is associated with increased burden of mental health disorders^{3,4}. The high risk of HIV among PWID can be explained by individual factors like needle sharing during injection, and structural factors including stigma and discrimination, criminalization, high exposure to human rights abuses; and a paucity of prevention and harm reduction programs^{5,6}. These structural level factors limit PWID engagement in prevention and treatment services, resulting in PWID having poorer HIV outcomes compared to other adults⁷. PWID additionally face significant social and economic challenges with high burden of homelessness or unstable housing and high incarceration rates². Finally, PWID have overlapping sexual risks with high levels of inconsistent condom use and sex work⁸.

While the specific needs of PWID have been widely explored and documented in high-income countries, limited data exist for countries across SSA^{2,9}. However, a review of IDU in six African countries found a high prevalence of high-risk behaviors including needle sharing and inconsistent condom use among PWID¹⁰. In addition to the paucity of evidence to guide programming, few PWID-centered programs exist⁹. A systematic review of interventions to prevent and manage HIV and HCV among PWID revealed that while more countries in SSA are investigating IDU (increased from 13 to 36 between 2007 and 2017), few countries are implementing PWID-focused disease prevention and treatment strategies (2 to 7 for needle and syringe programs, 4 to 8 for opioid substitution therapy, and even fewer for other interventions)¹¹. Thus, a greater focus should be placed on PWID programs including epidemiological and clinical research to guide implementation across SSA.

In Rwanda, HIV prevalence among reproductive aged adults has stabilized at 3% for the last decade, with the country being one of the few to achieve the UNAIDS 90-90-90 HIV elimination targets by 2020¹. However, similar progress has yet to be seen among key populations. Recent studies have demonstrated a high prevalence of HIV and other STIs and programmatic gaps among MSM, TGW and FSW¹²⁻¹⁴. Moreover, PWID have been the most overlooked in HIV

programming and research in Rwanda. Rwanda's HIV guidelines have a minimum package of services for both MSM and FSW, but no such program for PWID¹⁵. This lack of PWID-focused national programming, coupled with the criminalization of drug use or possession, further complicates programming in Rwanda¹. Thus, understanding and addressing the needs of PWID in Rwanda is a public health and human rights imperative.

We conducted this study to better inform future research and programming for PWID in Rwanda. The aim of this paper is to estimate the burden of HIV infection and examine IDU related behaviors associated with HIV among PWID in Kigali.

Methods

Study context, procedures, and population

This was a cross-sectional mixed methods study implemented by Health Development Initiative (HDI), a local non-governmental organization working with KPs in Rwanda. This study leveraged qualitative and quantitative methods to guide implementation of health programs for PWID in Rwanda. The specific objectives were to collect data on sociodemographic characteristics and IDU practices among PWID, to characterize the PWID population, and to provide an estimate of the HIV prevalence among PWID in Kigali.

Given the lack of a sampling frame and nonexistence of reliable epidemiological or program data to guide probability sampling methods for PWID, study participants were recruited through purposive and convenience sampling in Kigali city from October 2019- February 2020. Initial participants were recruited from clients who use HDI services in Kigali city. Upon recruitment, these participants were trained and encouraged to recruit their peers who injected drugs in the study. Further community outreach was conducted by HDI community liaisons in all the three districts of Kigali i.e., Nyarugenge, Kicukiro and Gasabo. Eligible participants were at least 18 years old, had injected drugs in the six months preceding the study, agreed to an HIV test, and gave written consent to participate in the study. The study was approved by the Rwanda National Ethics Committee N: 027/RNEC/2020

Data collection

Data collection was conducted in two HDI sites in Kigali city. After signing the informed consent form, participants underwent structured face-to-face interviews conducted by trained data collectors, and biological testing for HIV. The questionnaire comprised of questions related to sociodemographic characteristics and IDU history and practices in the months preceding the study. Participants were also asked about their need for, and access to, substance use disorder treatment programs. No personal identifying information was collected to protect the privacy of participants.

We performed HIV rapid testing for all participants who gave their consent, per the national guidelines. The screening test was Alere HIV Combo- Determine (Alere, Inc, Waltham, MA)

and the confirmatory test was HIV1/2 STAT-PAK (Medford, NY, USA) for participants who screened HIV-positive. Participants with a prior documented HIV diagnosis in a health facility were not retested. Participants who were newly found to be living with HIV were referred to a healthcare facility of their choice to initiate antiretroviral treatment (ART) and further medical management. Participants also received information on centers providing substance use disorder treatment in Rwanda. Upon completion of study procedures, participants received 2000 Frw as transport reimbursement.

Outcome Assessment

The outcome variable was HIV infection. HIV-negative status was defined only as testing HIV negative at time of the study. HIV-positive status was based on the testing conducted in the study or previously medically confirmed HIV-positive status.

Other variables of interest

Sociodemographic characteristics

Sociodemographic characteristics included age, biological sex, education, occupation, and self-reported sexual orientation.

Age was collected as a continuous variable but categorized into three groups for analytical purposes: 18-24, 25-35 and over 35 years. Sex was defined as female or male based on the sex assignment at birth. Sexual orientation was self-reported and categorized as heterosexual, homosexual, and bisexual. Education and occupation were analyzed as categorical variables with three groups each (Table 1).

IDU history and practices, access to treatment and other behaviors

Participants were asked the age at which they first injected drugs, the drug they first injected, source of the drug, and whether shared needles during their first drug injection. Overall injection history was assessed by estimating the duration of IDU for each participant and lifetime needle sharing history. Participants were also asked if they knew anyone who had died from a drug overdose. Participants were asked detailed questions about their primary drug of injection, other drugs used, and frequency of drug injection in the six months preceding the study. To assess injection frequency, participants were asked the number of times they injected per day, week, month, or year. Frequency of needle sharing, sharing of other injecting materials, and needle reuse were assessed using 5 item scales ranging from never, rarely, half the time, most of the time, and always. We also captured information on injection partnerships (i.e., sex partners, friends, relatives, drug dealer, strangers or other) and history of exchanging sex for drugs (Table 2). Participants were asked about their knowledge and use of substance use disorder treatment programs in Rwanda (Table 3). Finally, participants were asked questions assessing their HIV knowledge, HIV testing history and condom use during sex.

Analysis

We calculated crude estimates, including means and proportions, for sociodemographic characteristics, the outcome of interest and other covariates. Pearson's Chi-squared tests (χ^2) were used to compare demographic and IDU behaviors by biological sex, and an alpha level of 0.05 was used to attribute statistical significance. We applied Lowess smoothed non-parametric regressions to choose appropriate scales for age and duration of injection drug use. Since both variables showed an approximately linear association with HIV infection, they were both analyzed as continuous variables. All other variables were analyzed as binary or categorical variables. Table 4 summarizes all variables hypothesized to be associated with HIV infection and included in our analyses.

Bivariable Poisson regression models with robust variance estimation were fitted to compute prevalence ratios (PR) and 95% confidence intervals (CI) determining the association between HIV infection and sociodemographic factors and IDU practices. Poisson regressions were used after log binomial models failed to converge. The final model was constructed using variables that were associated with the outcome if $P < 0.1$ in the bivariable analyses. All the analyses were performed with Stata Version 14.2 (StataCorp, College Station, TX) statistical package.

Results

Sociodemographic characteristics and HIV infection

A total of 322 PWID were recruited in the study, but these analyses were restricted to 307 participants for whom HIV status information was available (five participants refused testing and 10 were missing testing results). The median age of participants was 28 years (IQR:24–31) and 81% (248) were male. All sociodemographic characteristics are summarized in table 1.

The prevalence of HIV in this group was 9.5% (95%CI: 8.7-9.3).

Injection drug history

Median age at first injection was 23 (IQR:20-27), but 17% (53) of participants had their first injection before reaching 18. The majority of participants, 57% (176) had been injecting for four or more years. Nearly all, 99% (304), injected heroin their first time and 24% (73) shared needles with someone at their first injection.

In the six months preceding the study, heroin was the primary drug of choice for 99% (303) of participants. However, 10% (31) and 4% (12) of participants, respectively, reported injecting cocaine and methamphetamine as well. Many participants, 30% (93), had used a drug combination in the six months before the study. The most common combination of drugs was heroin and marijuana, reported by 23% (70) of participants, while alcohol use was reported in combination with heroin by 9% (28) of participants. IDU frequency was high with 95% (293) reporting at least one injection per day in the previous six months.

Overall, 31% (94) of participants shared needles while 27% (83) shared other injection paraphernalia in the previous six months. However, up to 91% (280) of participants reported ever sharing needles in their lifetimes. Furthermore, 33% (103) reported reusing needles previously used for injecting. Most participants, 98% (301) reported getting sterile needles from pharmacies and 20% (61) reported also getting needles from their networks, including friends and sex partners, among others. However, 34% (101) of participants reported not always having access to sterile needles for injection purposes when they needed them. Finally, 31% (94) of participants reported exchanging sex for drugs in the six months before the study (Table 2). Females were more likely than men to report exchanging sex for drugs (60% vs 25%, χ^2 p value < 0.0001). There were no other significant differences between males and females on other variables assessing IDU practices and history.

The majority of participants, 60% (184), reported having tried to reduce or quit IDU in the previous six months. However, only 5% (14) had enrolled in a treatment program within this timeframe. Overall, 43% (133) of participants knew someone who died from a drug-related overdose (Table 3).

Regarding HIV related knowledge and behavior, 87% (268) reported knowing that IDU was a risk factor for HIV infection. Over half of participants, 65% (198), reported inconsistent condom use in the six months preceding the study.

Bivariable analysis

In the bivariable analyses, sociodemographic characteristics among PWID that were significantly associated with HIV were age, education, and marital status. Each additional year increase in age was associated with a 5% increase in HIV infection (PR: 1.05; 95% CI: 1.01–1.09). Additionally, PWID with secondary education had lower prevalence of HIV (PR: 0.25; 95% CI: 0.07–0.94) compared to those with primary education or less. PWID who were divorced, separated, or widowed had a four times higher burden of HIV compared to individuals who were single (PR: 4.64; 95% CI: 2.25–9.58). There were no significant associations between HIV infection and biological sex, occupation, or sexual orientation in this group (Table 4).

Duration of drug injection and needle sharing in the six months preceding the study were both significantly positively associated with HIV infection. Each additional year of drug injection was associated with a 6% increase in HIV infection (PR: 1.06; 95% CI: 0.99–1.11). Additionally, PWID who shared needles half the time or more in the six months preceding the study were three times more likely to be living with HIV compared to those who had not shared needles during that time frame (PR: 3.34; 95% CI: 1.53–7.28). There were no significant associations between HIV and age at first injection, number of sharing partners, or selling sex in the six months preceding the survey (Table 4).

Multivariable analysis

In the final multivariable model, sharing needles half the time or more during drug injection remained positively associated with HIV infection (aPR: 2.67; 95% CI: 1.23–5.78). (Table 4)

Discussion

This study is one of the first to characterize the population of PWID in Rwanda and to describe the burden of HIV in this community. Moreover, it clearly demonstrates existence of individual risk factors known to be associated with HIV, including needle sharing and inconsistent condom use. These practices highlight substantial potential risks of onward transmission and acquisition of HIV and other bloodborne infections among PWID in Rwanda. These results show an urgent need for implementation of evidence-based harm reduction strategies and other individual-, network-, and structural-level interventions to reduce morbidity and mortality among PWID in Rwanda.

In this convenience-based sample, PWID carried a disproportionate burden of HIV over three times what is observed in the general population.¹⁶ These findings are consistent with other African studies, underscoring the need to address the HIV prevention and treatment needs of PWID to close HIV elimination gaps¹⁷. However, other countries have reported higher HIV burden among PWID (e.g., Kenya: 14-20%; Mozambique: 20-50%; South Africa: 21%), likely reflecting the overall higher burden of HIV in these countries compared to Rwanda¹⁸⁻²¹.

Injection partners with whom one shares injection equipment, is a primary mode of HIV acquisition. However, risk of HIV and other bloodborne infections can be further compounded by sexual risk behaviors (e.g., condomless sex). Our results suggest that consistent condom use in this population is low, which is expected given that research suggests riskier sexual practices are associated with substance abuse²². Globally, studies indicate that sexual risks are elevated among PWID in sub-Saharan Africa relative to other regions, highlighting the importance of understanding the intersecting impact of sexual and injection drug risks among PWID in Rwanda¹⁷. Implementing sexual health programs, like condom distribution and HIV/STI management, could mitigate the added sexual risks that PWID face. Successes of the Rwanda HIV program in the general adult population could be leveraged to develop initiatives tailored to PWID needs.

Importantly, we observed a high prevalence of risky IDU practices. Nine out of ten participants reported ever sharing needles, while over one third reported sharing needles in the prior 6 months. Consistent with existing literature from the region, needle sharing was positively associated with HIV infection in this study^{18,19,21}. A high proportion of participants also reported reusing needles, which is known to be associated with severe infections including abscesses, septicemia, and infective endocarditis²³⁻²⁵. Taken together, these data demonstrate the urgency for implementing comprehensive harm reduction interventions in Rwanda, particularly needle and syringe service programming (NSP) to provide safe injection equipment and education on safer injection techniques²⁶. NSPs providing sterile needles and other drug paraphernalia have been shown to effectively reduce unsafe injection practices and injection frequency, to facilitate

linkage to substance use disorder treatment programs and other Medical Assisted Treatment (MAT), and to be cost effective²⁷⁻²⁹.

In addition to NSP, there is a necessity for overdose prevention and management and substance use disorders treatment in Rwanda. Despite Naloxone already being available in some pharmacies in Rwanda³⁰, nearly half of participants reported knowing someone who died from a drug-related overdose. This calls for immediate introduction of overdose prevention and treatment programs and strategies to optimize distribution and use of Naloxone in Kigali. Community-based overdose prevention and response programs have been implemented in other settings, and there is evidence that these programs can save lives³¹⁻³³. Finally, over half of participants reported wanting to reduce or quit drug injection practices, however only 15% reported ever attending a substance use treatment program, highlighting a need for increased coverage and availability of programs such as MAT. Heroin was the primary drug of choice, as observed in other countries in the region, unlike in the United States or other Western countries where synthetic/pharmaceutical opioids, often acquired as prescription medication, are injected with higher frequency³. Additionally, some participants reported injecting cocaine and methamphetamine. It is possible that there are more drug types being used in Kigali that are not reported in this study, most likely because participants were not asked about them during interviews. Given the high frequency of injection reported (i.e., most participants injected daily), and the likely high number of overdoses, a comprehensive study evaluating the types of drugs available in Kigali and their chemical composition is needed to inform programming for PWID in Kigali.

Another contribution of this study is characterizing the demographic characteristics of PWID in Kigali. Almost one fifth of participants reported their first injection before 18 years of age. The 2020 World Drug Report highlighted the growing demand for injection drug use, particularly among young adults in African countries^{3,34}. This is evidenced by the fact that almost half of participants in our study reported injecting drugs for fewer than 3 years. Additionally, although there was no statistical association between biological sex and HIV infection, female PWID in our study reported a higher prevalence of selling sex for drugs. Gender differences in the risk of HIV acquisition among PWID have been documented in other settings^{35,36}. Further studies detailing social and health experiences of different demographic subgroups of PWID in Rwanda are needed.

The high prevalence of selling sex among female PWID in this study is consistent with findings from other studies that have documented high levels of soliciting sex in exchange for drugs among female PWID^{36,37}. Additionally, the fact that some PWID in the sample self-identify as MSM suggest existence of groups of PWID who may have substantial sexual risk of HIV and other STI compared to other PWID in Rwanda. For instance, PWID who also engage in sex work have been found to be at higher risk of HIV compared to other PWID⁸. Thus, programs should be cognizant of this complex interplay of sexual identities; and sexual and IDU practices to offer optimal interventions to all members of KP groups.

Our study has several limitations. First, our sample is cross-sectional and convenience-based. We are therefore unable to make inferences to the larger PWID population in Kigali. Furthermore, the cross-sectional nature of the study limits our ability to make temporal inferences between the variables of interest and HIV infection. Second, separate from HIV testing, our measurers are self-reported and may be subject to recall or social desirability bias. However, we observed high prevalence of injection and needle sharing behaviors, thus providing a benchmark with which to inform programmatic planning for PWID in Rwanda. Our study was also limited in that it did not collect information on the behaviors of injection partners. The importance of injection drug networks on the transmission and acquisition of bloodborne infections, including HIV, and the social diffusion of behaviors and other network norms, have been well documented in other settings³⁸. Given that over half of participants reported injecting with someone else at first injection, indicates the potential for implementing network-based interventions to reach PWID with services and educational messages early in their injection history. Finally, while the study identifies a proportion of the sample that are aware of their HIV status, we are unable to determine HIV outcomes further downstream of the HIV care continuum. In particular, viral suppression could serve as a marker to gauge the success of the HIV treatment program in this population. The lack of HBV and HCV testing in this study presents another limitation given the high burden of these infections among PWID globally¹⁷. Despite these limitations, our study provides critical information to understand the HIV programming needs of PWID in Kigali.

Future research should leverage respondent-driven sampling, or other sampling approaches used to reach and estimate the size of historically hidden populations without a known sampling frame^{39,40}. Stronger sampling approaches could facilitate data collection for larger epidemiological studies, enabling estimation of the prevalence of HIV, HBV, HCV, and other health (e.g., viral suppression) and social outcomes (e.g., mental health), as well as the impact of structural factors (e.g., stigma, criminalization) on these outcomes at the community or population level. Estimating the size of the PWID population would allow for better programmatic planning to address the HIV and other health needs of PWID in Rwanda.

Conclusion

The findings of this study call for immediate action. PWID have a high HIV prevalence and self-reported injection practices associated with substantial onward risk of transmission and acquisition of HIV and other bloodborne infections. Implementation of evidence-based comprehensive harm reduction programs is not only a public health emergency but also a human rights and moral imperative. Few African countries have adopted needle and syringe exchange programs, and even fewer have government-led MATs. Rwanda should join this list to save lives of PWID and generate evidence that will inform programming in other African countries.

Funding

This study was internally funded by HDI resources. CB is supported in part by the Desmond M. Tutu Professorship at Johns Hopkins University. NPM is supported through T32 NRSA Pre-doctoral Training Fellowship in HIV Epidemiology and Prevention Sciences (5T32AI102623-08) within the Johns Hopkins University Center for Public Health and Human Rights. SB is supported in part by a grant from the National Institutes of Mental Health (R01MH110358).

Competing interests

The authors have no competing interests to disclose

Acknowledgments

We are grateful to all study participants for their time and for sharing their personal histories with us.

Authors' contribution

VN, AAM, SM, AR, AK, AN conceived the study. SM, VN, AK led the implementation of the study. JOTR, NPM, NO analyzed the data. JOTR wrote the first draft of the paper. All authors edited and approved the manuscript.

Table 1. Baseline characteristics of PWID in Kigali, Rwanda, N:307

Characteristic	N	%	Not living with HIV N (%)	Living with HIV N (%)
Age in years				
18-24	83	27.2	80 (96.4)	3 (3.6)
25-34	188	61.6	167 (88.8)	21 (11.2)
>35	34	11.2	30 (88.2)	4 (11.8)
Biological sex				
Female	56	18.2	48 (85.7)	8 (14.3)
Male	251	81.8	230 (91.6)	21 (8.4)
Education				
Primary education or less	47	15.3	40 (85.1)	7 (14.9)
Some secondary education	79	25.7	76 (96.2)	3 (3.8)
Completed secondary or above	181	58.9	162 (89.5)	19 (10.5)
Marital status				
Single	252	82.9	232 (92.1)	20 (7.9)
Cohabiting/Married	33	10.8	31 (93.9)	2 (6.1)
Divorced/Separated/Widow	19	6.3	12 (63.2)	7 (36.8)
Occupation				
Unemployed	169	55	154 (91.1)	15 (8.9)
Student	10	3.3	10 (100)	0 (0)
Part time/Full time employee	128	41.7	114 (89.1)	14 (10.9)
Self-reported sexual orientation				
Heterosexual	215	70.3	198 (92.1)	17 (7.9)
Homosexual	35	11.4	31 (88.6)	4 (11.4)
Bisexual	56	18.3	48 (85.7)	8 (14.3)

Table 2. Injecting drug use history and practices among PWID in Kigali, Rwanda, N:307

Variable	N	%
<i>First drug injection</i>		
Age at first injection		
Less than 18	53	17.3
18-24	132	43
>25	122	39.7
Drug injected the first time		
Heroin	304	99.1
Cocaine	2	0.6
Methamphetamine	1	0.3
Person who performed the injection the first time		
Self	134	43.7
Friend	146	47.5
Sex partner	20	6.5
Other	7	2.3
Needle sharing the first time		
No	234	76.2
Yes	73	23.8
Source of drug the first time		
Bought them from someone	259	84.4
Received them for free	41	13.4
Traded them for sex	5	1.6
Refused to answer	2	0.6
<i>Injecting drug history</i>		
Duration of drug injection		
Less than 3	129	42.3
4-5 years	105	34.4
Over 5	71	23.3
Needle sharing history		
Never shared needles	27	8.8
Ever shared needles	280	91.2
<i>Injection drug practices in the previous six months</i>		
Primary drug of injection in the previous six months		
Heroin	303	98.7
Cocaine	2	0.65
Methamphetamine	2	0.65
Heroin injection in the previous six months		
No	5	1.6
Yes	302	98.4
Cocaine injection in the previous six months		
No	271	89.7

Yes	31	10.3
Methamphetamine injection in the previous six months		
No	282	95.9
Yes	12	4.1
Drug injected the first time		
Heroin	304	99.1
Cocaine	2	0.6
Methamphetamine	1	0.3
Used a Drug combination		
No	212	69.5
Yes	93	30.5
Needle sharing in the previous six months		
Never	213	69.4
Rarely	60	19.5
Half of the time or more	34	11.1
Needle reuse in the previous six months		
Never	204	66.5
Rarely	75	24.4
Half of the time or more	28	9.1
Selling sex for Drugs in the previous six months		
No	204	68.5
Yes	94	31.5

Table 3. Need of and Access to Drug Addiction Treatment programs among PWID in Kigali, Rwanda, N:307

Variable	N	%
Tried to reduce or quit drug consumption in the previous 6 months		
No	122	39.9
Yes	184	60.1
Aware of any Drug addiction treatment programs		
No	205	66.7
Yes	45	14.7
Do not know	57	18.6
Drug Addiction treatment in the previous six months *		
No	290	95.4
Yes	14	4.6
Unable to access Drug Addiction treatment in the previous six months		
No	259	84.4
Yes	48	15.6
Ever enrolled in a Drug Addiction treatment program		
Never been treated	263	85.7
Ever been treated	21	6.8
Refused to answer	23	7.5
Know someone who died from a drug overdose		
No	73	24
Yes	133	43.8
Don't know	98	32.2

Table 4: Factors associated with HIV infection among PWID in Kigali, Rwanda, N:307

	N Living with HIV	% Living with HIV	Unadjusted PR (95% CI)	p- value	Adjusted PR (95%CI)	p- value
Sociodemographic characteristics						
Age in years			1.05 (1.01-1.09)	0.02	0.98 (0.91-1.07)	0.769
Biological sex						
Female	8	14.3	Ref			
Male	21	8.4	0.58 (0.27-1.25)	0.169		
Education						
Primary education or less	7	14.9	Ref		Ref	
Some secondary education	3	3.8	0.25 (0.07-0.94)	0.04	0.31 (0.09-1.05)	0.06
Completed secondary or above	19	10.5	0.71 (0.31-1.57)	0.395	0.64 (0.27-1.50)	0.303
Marital status						
Single	20	7.9	Ref		Ref	
Cohabiting/Married	2	6.1	0.76 (0.18 - 3.13)	0.708	0.81 (0.21-3.26)	0.769
Divorced/Separated/Widow	7	36.8	4.64 (2.25 - 9.58)	0.001	4.56 (1.91-10.90)	0.001
Occupation *						
Unemployed	15	8.9	Ref			
Employed	14	10.9	1.23 (0.62-2.46)	0.554		
Self-reported sexual orientation						
Heterosexual	17	7.9	Ref			
Homosexual	4	11.4	1.44 (0.52-4.05)	0.484		
Bisexual	8	14.3	1.81 (0.82-3.97)	0.141		
Drug Injection related behaviors, access to needles and condom use						
Age at first injection						
Before 18 years	5	9.4	Ref			
18 to 24 years	12	9.1	1.36 (0.57-3.23)	0.48		
Over 25 years	12	9.8	1.82 (0.75-4.37)	0.183		
Duration of drug injection						
Years injecting drugs			1.06 (0.99-1.11)	0.055	1.05 (0.93-1.18)	0.407
Needle sharing in the previous 6 months						
Never	15	7.1	Ref		Ref	
Rarely	6	10	1.42 (0.57-3.51)	0.447	1.39 (0.48-4.04)	0.536
Half the time or more	8	23.5	3.34 (1.53-7.28)	0.002	2.67 (1.23-5.78)	0.013
Number of needle-sharing partners in the previous 6 months						
None	7	11.1	Ref			
One to two	15	8.2	0.74 (0.31-1.73)	0.484		

References

1. UNAIDS. *2020 Global AIDS Update □— Seizing the moment □— Tackling entrenched inequalities to end epidemics*. UNAIDS;2020.
2. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *The Lancet Global Health*. 2017;5(12):e1192-e1207.
3. World Drug Report 2020. 2021.
4. J G, S L, A P, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. *Addiction (Abingdon, England)*. 2019;114(1).
5. Jürgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights. *The Lancet*. 2010;376(9739):475-485.
6. WHO. *ATLAS on substance use 2017: resources for the prevention and treatment of substance use disorders*. World Health Organization;2017.
7. Malta M, Ralil da Costa M, Bastos FI. The paradigm of universal access to HIV-treatment and human rights violation: how do we treat HIV-positive people who use drugs? *Curr HIV/AIDS Rep*. 2014;11(1):52-62.
8. Campeau L, Blouin K, Leclerc P, et al. Impact of sex work on risk behaviours and their association with HIV positivity among people who inject drugs in Eastern Central Canada: cross-sectional results from an open cohort study. *BMJ Open*. 2018;8(1):e019388.
9. Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *The Lancet Global Health*. 2017;5(12):e1208-e1220.
10. Dewing S, Plüddemann A, Myers BJ, Parry CDH. Review of injection drug use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and Tanzania. <http://dxdoiorgproxy1libraryjhuedu/101080/09687630500480228>. 2009.
11. S L, A P, J L, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *The Lancet Global health*. 2017;5(12).
12. Twahirwa Rwema JO, Lyons CE, Herbst S, et al. HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross-sectional study. *Journal of the International AIDS Society*. 2020;23(S6).
13. Twahirwa Rwema JO, Herbst S, Hamill MM, et al. Cross-sectional assessment of determinants of STIs among men who have sex with men and transgender women in Kigali, Rwanda. *Sexually Transmitted Infections*. 2021:sextrans-2020-054753.
14. Ingabire R, Parker R, Nyombayire J, et al. Female sex workers in Kigali, Rwanda: a key population at risk of HIV, sexually transmitted infections, and unplanned pregnancy. *Int J STD AIDS*. 2019;30(6):557-568.
15. Health Mo. *National Guidelines for Prevention and Management of HIV*. Kigali, Rwanda: Ministry of Health - Rwanda Biomedical Center; 2016 2018.
16. NISR. *Rwanda Demographic and Health Survey 2014-15 - Final Report*. Kigali - Rwanda: National Insitute of Statistics of Rwanda
- 2016.
17. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *The Lancet Global Health*. 2017;5(12):e1192-e1207.

18. Baltazar CS, Horth R, Boothe M, et al. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. *BMC infectious diseases*. 2019;19(1):1-13.
19. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV prevalence, estimated incidence, and risk behaviors among people who inject drugs in Kenya. *Journal of acquired immune deficiency syndromes (1999)*. 2015;70(4):420.
20. Tun W, Sheehy M, Broz D, et al. HIV and STI prevalence and injection behaviors among people who inject drugs in Nairobi: results from a 2011 bio-behavioral study using respondent-driven sampling. *AIDS and Behavior*. 2015;19(1):24-35.
21. Scheibe A, Young K, Moses L, et al. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. *Harm reduction journal*. 2019;16(1):1-11.
22. Brookmeyer KA, Haderxhanaj LT, Hogben M, Leichter J. Sexual risk behaviors and STDs among persons who inject drugs: a national study. *Preventive medicine*. 2019;126:105779.
23. Wurcel AG, Anderson JE, Chui KK, et al. Increasing infectious endocarditis admissions among young people who inject drugs. Paper presented at: Open forum infectious diseases 2016.
24. Tan C, Shojaei E, Wiener J, Shah M, Koivu S, Silverman M. Risk of new bloodstream infections and mortality among people who inject drugs with infective endocarditis. *JAMA network open*. 2020;3(8):e2012974-e2012974.
25. Wright T, Hope V, Ciccarone D, Lewer D, Scott J, Harris M. Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. *Plos one*. 2020;15(7):e0235350.
26. Drugs UNOo, Crime INoPWUD, Joint United Nations Programme on HIV/AIDS. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. In: United Nations Office on Drugs and Crime Vienna; 2017.
27. Strathdee SA, Celentano DD, Shah N, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. *Journal of urban health : bulletin of the New York Academy of Medicine*. 1999;76(4):448-460.
28. Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. *Journal of Substance Abuse Treatment*. 2000;19(3):247-252.
29. Riley ED, Kral AH, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. *J Urban Health*. 2010;87(4):534-542.
30. Health RMo. National List of Essential Medicines for Adults 6th Edition. In. Kigali, Rwanda 2015.
31. Bennett AS, Bell A, Tomedi L, Hulse EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. *J Urban Health*. 2011;88(6):1020-1030.
32. Leece PN, Hopkins S, Marshall C, Orkin A, Gassanov MA, Shahin RM. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. *Can J Public Health*. 2013;104(3):e200-e204.
33. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. *J Addict Med*. 2014;8(3):153-163.
34. DRUGS UNOO, LABOR. *WORLD DRUG REPORT 2020 (SET OF 6 BOOKLETS)*. UN; 2021.
35. Des Jarlais DC, McKnight C, Feelemyer J, et al. Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001–2005 and 2011–2015. *Drug and alcohol dependence*. 2018;185:391-397.

36. Jain JP, Abramovitz D, Strathdee SA, et al. Sex Work as a Mediator Between Female Gender and Incident HIV Infection Among People Who Inject Drugs in Tijuana, Mexico. *AIDS & Behavior*. 2020;24(9).
37. Atkinson J, McCurdy S, Williams M, Mbwambo J, Kilonzo G. HIV risk behaviours, perceived severity of drug use problems, and prior treatment experience in a sample of young heroin injectors in Dar es Salaam, Tanzania. *African journal of drug and alcohol studies*. 2011;10(1).
38. Ghosh D, Krishnan A, Gibson B, Brown SE, Latkin CA, Altice FL. Social Network Strategies to Address HIV Prevention and Treatment Continuum of Care Among At-risk and HIV-infected Substance Users: A Systematic Scoping Review. *AIDS and Behavior*. 2017;21(4).
39. Heckathorn DD. Respondent-Driven Sampling II: Deriving Valid Population Estimates from Chain-Referral Samples of Hidden Populations. *Social Problems*. 2002;49(1):11-34.
40. Heckathorn DD, Wangroongsarb P, Thwing J, et al. Respondent-Driven Sampling: A New Approach to the Study of Hidden Populations. *Social Problems*. 1997;44(2):174-199.